M&A Deal Summary |
|
|---|---|
| Date | 2006-09-26 |
| Target | Schwarz Pharma AG |
| Sector | Medical Products |
| Buyer(s) | UCB |
| Deal Type | Add-on Acquisition |
| Deal Value | 5.6B USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1928 |
| Sector | Healthcare Services |
| Employees | 9,000 |
| Revenue | 5.3B EUR (2023) |
UCB is a biopharma focused on severe diseases with operations in approximately 40 countries. UCB was incorporated in 1928 and is based in Brussels, Belgium.
| DEAL STATS | # |
|---|---|
| Overall | 5 of 11 |
| Sector (Medical Products) | 3 of 3 |
| Type (Add-on Acquisition) | 4 of 9 |
| Country (Germany) | 1 of 1 |
| Year (2006) | 1 of 1 |
| Size (of disclosed) | 1 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-01-17 |
UCB - Bioproducts Manufacturing Division
Brussels, Belgium UCB-Bioproducts has been active in chemical peptide manufacturing for over 20 years, and has developed considerable capabilities and expertise during this period. This division, with approximately 300 employees, is located in Braine-l'Alleud just outside of Brussels, Belgium. |
Sell | €120M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-01-22 |
UCB - Pharmaceutical Brands
Belgium UCB - Pharmaceutical Brands include Keppra for the treatment of epilepsy and Xyzal and Zyrtec for the treatment of allergic rhinitis. The acquired products will be sold in multiple territories. Asia Pacific territories include Malaysia, Taiwan, Thailand and Vietnam. Middle Eastern territories include Egypt, Pakistan, Saudi Arabia and United Arab Emirates. African territories include South Africa. Latina territories include Argentina and Chile. Territories excluded are China, South Korea, India, Australia, Mexico, Brazil and Malta. |
Sell | €515M |
